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Notably, the time from RP to BR was not significant. The probability 
of 5-yr bRFS was significantly predicted by overall PSADT (p<0.0001, 
by logistic regression), with the optimal cut-off set at 5.79 months 
(sensitivity=0.67, specificity=0.72) by ROC analysis.The PSADTs, 
computed at different time points or with a different number of 
observations were always significantly correlated to the overall 
PSADT, (Spearman's correlation). However, only the PSADTs computed 
at ≥9 months or based on ≥4 observations emerged as significant 
predictors of 5-yr bRFS (logistic regression) with most informative cut-
offs of 4.6 and 6.58 months, respectively. Finally, the median PSADT 
increased as a function of time and number of observations, thus 
suggesting an effect of the dynamic selection of the patients 
(apparently, those with the poorer prognosis had started SRT earlier). 
Conclusions: Only PSADT calculated ≥9 months after the first value 
≥0.10 ng/mL and/or on ≥4 observations resulted to be predictive of 
the risk of treatment failure following SRT. This may limit its role in 
selecting patients to be addressed to very early SRT. Of note, our 
optimal cut-offs ranged from 4.6 to 6.58 months. 
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Purpose/Objective: To retrospectively evaluate and compare the 
incidence of acute genito-urinary (GU), upper gastrointestinal (uGI) 
and rectal (lGI) injuries of hypofractionation by volumetric modulation 
arc therapy or VMAT (Hypo-RapidArc group) and conventional 
fractionation by three dimensional conformal radiotherapy (3DCRT 
group) in patients with localized prostate cancer treated with 
prostatic bed irradiation, after radical prostatectomy.  
Materials and Methods: Between 2007 and 2012, 84 consecutive 
patients with clinically localized prostate cancer patients submitted 
to radical prostatectomy were irradiated to prostate bed: 41 with 
3DCRT and 43 with VMAT by RapidArc. The median age was 67 and 
68,5 years for 3DCRT and Hypo-RapidArc group respectively. The 
median dose to the prostatic bed was 70 Gy (70 - 76) with 2 Gy per 
fraction in 3DCRT group and 70Gy (70 – 72,4) with 2.5Gy (2.5 – 2.55) 
per fraction in the Hypo-RapidArc group. After radical prostatectomy, 
the median time to RT was 15 and 16 months respectively in 3DCRT 
and Hypo-RapidArc group. Acute GU, uGI e lGI toxicities after 
radiation treatment were evaluated using RTOG/EORTC medical 
scoring system.  
Results: Acute G2 GU toxicities were better in Hypo-RapidArc group 
compared to 3DRCT group: 12% versus 17% respectively in the two 
groups. Inversely, for Acute G2 intestinal toxicities, 3DCRT was well 
tolerated: for uGI no G2 were found in 3DCRT versus 7% in Hypo-
RapidArc group; for lGI G2 toxicities7% in 3DCRT versus 18% in Hypo-
RapidArcgroup. No G3 or greater toxicities were found in both groups. 
In both groups the PTV coverage is suitable: PTV mean dose is 
99.4±1.0% and 99.8±0.9% and V95% 96.3±3.6% and 95.7±8.9 for 3DRCT 
and RA group respectively. For 3DRTC group the Rectum received a 
mean dose of42.1±9.4 Gy (with V65Gy equal to 26.9±10.0 %) and the 
Bladder received 69.3±17.2Gy in mean (with the V65Gy equal to 
45.0±19.5%); and for RA group the dose decreased to 37.2±5.2 Gy 
(V65Gy 9.6±5.1%) and 39.2±13.4 (V65Gy25.2±14.4%) for Rectum and 
Bladder. 
Conclusions: The results of our study of 84 patients have shown that 
acute G2 GU are reduced using hypofractionation by RapidArc 
compared to conventional fractionation by 3DCRT, while acute G2 GI 
toxicities remains significantly better for the last one. Remarkable is 
the absence of G3 using hypofractionation by RapidArc as well as 
recorded previously with conventional fractionation by 3DCRT. Longer 
term data are awaited for late toxicity profiles and clinical efficacy in 
Hypo-RapidArc group of patients.  
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Purpose/Objective: To asses the effectiveness of online monitoring of 
prostate rotation as an indicator of the need for adaptive replanning 
in prostate patients treated with IMRT; to evaluate the possibility to 
predict large interfraction prostate rotations based on rectal filling on 
the planning CT. 
Materials and Methods: From a population of 640 prostate cancer 
patients treated with IMRT combined with online marker-based setup 
correction, 26 patients who exhibited frequent and large (>10 °) 
prostate rotations were selected for a repeat CT scan and adaptive 
replanning. The effectiveness of adaptive replanning of these patients 
was assessed by evaluating the relative decrease in the frequency of 
large prostate rotations. The correlation between rectal filling as 
determined on the planning CT and the frequency of large prostate 
rotations was analyzed. Also, for these 26 re-planned patients the 
second planning CT scan was imported in the initial IMRT plan and the 
target coverage was evaluated in order to assess the potential impact 
of no action on this group of patients.  
Results: For the 26 patients that were re-planned, the frequency of 
large prostate rotations significantly decreased by 80.7% on average 
(p<0.001) during the fractions treated with the adapted plan. No 
significant correlation was found between the rectum volume, cross-
section or diameter on the planning CT and the frequency of prostate 
rotations (p>0.05), however there seems to be a higher risk of large 
rotations in patients with a rectum diameter larger than 5 cm at the 
level of the prostate base (p=0.03). If these patients had not been re-
planned, due to the systematic change in prostate orientation the PTV 
coverage would have decreased to 90.2% on average, although the 
CTV would remain adequately covered for all patients. 
Conclusions: For prostate cancer patients treated with IMRT 
combined with fiducial-based online position verification, a relatively 
simple prostate rotation monitoring protocol is sufficient to select the 
patients in need of adaptive replanning. Rectal filling on the planning 
CT scan is not a significant predictor of the frequency of large 
prostate rotations, although patients with a large diameter of the 
rectum on the planning CT seem to have a higher chance of having 
large prostate rotations. 
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Purpose/Objective: As male life expectancy increases throughout the 
developed world the incidence of prostate cancer is also increasing. 
Better diagnostics and raised public awareness has also contributed to 
this. A significant survival benefit favouring hormone therapy and 
radical radiotherapy over hormone therapy alone in locally advanced 
prostate cancer has been shown in recent studies. Radical 
radiotherapy technology for prostate cancer has evolved significantly 
aiming to reduce toxicity to normal tissues. Taking 10 year survival as 
the standard for assessing the use of radical treatment, we looked at 
the outcomes of patients who received radical radiotherapy for 
prostate cancer commencing after their 80th birthday. 
Materials and Methods: Data was collected retrospectively of all 
patients treated with radical radiotherapy for prostate cancer after 
their 80th birthday at our centre. From 2001 to 2012 a total of 25 
patients were suitable for inclusion. Complete data was available for 
20 patients. Key measures were patient’s prostate cancer risk 
category, predicted 10 year survival (based on Charlson comorbidity 
index) and actual disease free survival.  
Results: The mean age of patients was 80.76 years (range: 80 to 84). 
Patients received external beam radiotherapy as per local guidelines 
at a dose of 74 Gray in 37 fractions (80% of cases). Patients treated 
earlier received treatment doses ranging from 64 Gray in 32 fractions 
to 70 Gray in 30 fractions. 84% of patients had stage T3 disease, PSA≥ 
20ng/ml or Gleason score of ≥ 8 making them high risk according to 
National Institute for Clinical Excellence (NICE) criteria. The 
remaining patients were categorised as intermediate risk. No patients 
had nodal or distant metastases on imaging. All patients had a 
predicted 10 year survival of ≤ 2.25%, based on the Charlson 
comorbidity index. It is known that 4 patients have died. In 2 cases, 
the cause of death was unrelated; one from primary lung cancer and 
one from oesophageal cancer. The median disease free survival was 24 
months (range: 4 to 104). Median follow-up was 22 months. 
Conclusions: Patients in this age group have a low 10 year survival 
even without the presence of prostate cancer. By including 
intermediate to high risk prostate cancer, as in this series, this 
becomes even less. However, this 12 year series demonstrates that 
with careful selection a reasonable disease free survival can be 
achieved in this group of elderly men. Rather than basing decisions on 
predicted 10 year survival, radical radiotherapy should be carefully 
discussed with men over 80 with potentially curable prostate cancer 
on a patient by patient basis. We intend to create a prospective 
database of such patients in the future to further investigate the 
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benefit and toxicity of the addition of radiotherapy over hormones 
alone in this group. 
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Purpose/Objective: Prostate cancer patients (pts) under 70 years are 
more often candidates to surgery rather than radiotherapy (RT). We 
analyzed the results of ≤ 70 years patients with localized disease to 
demonstrate that RT is a valid alternative to surgery also in younger 
men.  
Materials and Methods: From January 1988 to December 2009, 214 
pts with T1-2N0M0 prostate cancer were treated with 3-5 fields 
conformal RT. The median baseline PSA level was 10,4 ng/ml (range 
0.2–254), Gleason score (GS) was: 2-6 in 114 pts, 7 in 37 pts, and 8-10 
in 18 pts. During the years the dose to the prostate was gradually 
increased from 60 Gy to 76 Gy. Forty-eight pts (22,4%) received 60-68 
Gy and 166 (77,6%) 70-76 Gy in 2 Gy daily fractions. Biochemical 
failure was defined according to ASTRO consensus criteria. Acute and 
late toxicity were graded according to the RTOG and EORTC criteria. 
Moreover we investigated the effects of patient and treatment related 
risk factors on acute and late toxicity.  
Results: The median follow-up was 105 months (range 14.2-180). 
Biochemical relapse occurred in 65 pts (30.4%), local failure in 8 
(3.7%), regional failure in 2 (0.9 %), distant metastases in 20 (9.3 %). 
The 5 and 10 year biochemical relapse free survival (bRFS) for all 214 
pts were 80 and 61.9% respectively. In univariate analysis initial PSA 
(≤10 vs>10 ng/ml, p=0.006) and PSA nadir (< 1 vs ≥ 1 ng/ml, p=0.023) 
but not age (≤ 65 vs 65-70 years) were significant factors for 
biochemical relapse. The 5 and 10 years bRFS were 84.4% and 66.7% 
when PSA nadir was <1 ng/ml, 60.9% and 43% respectively, when it 
was ≥ 1 ng/ml ( p<0.001). In multivariate analysis risk factors for 
biochemical relapse were initial PSA value ( p<0.001) and radiation 
dose (p=0.05). The mean cancer specific survival (CSS) of all pts was 
231.05 months. The CSS rate at 5 and 10 were 98.4 % and 93.2% 
respectively. In univariate analysis for CSS only PSA nadir was a 
significant factor (p<0.001). PSA nadir (p=0.019) and low radiation 
dose (p=0.037) were predictive for distant metastases in univariate 
analysis, while in multivariate analysis only initial PSA was significant 
(p=0.041). The median overall survival (OS) was160.2 months (range 
139.7-180.7). The OS rate at 5 and 10 were 91.8 % and 75.8% 
respectively.  
Acute genitourinary (GU) and gastrointestinal (GI) toxicities occurred 
in 105 (49%) and 98 pts (45.8%), respectively. There were no cases of 
Grade III or IV GU toxicity. There were 2 cases of Grade III GI toxicity . 
Late GU and GI toxicities occurred in 17(7.9%) and 20 (9.3%) patients 
respectively. There was one patient with Grade III GI toxicity and 2 
pts (0.9%) with Grade III GU. Risk factors for late toxicity were age 
and RT dose and technique while they were not related to acute 
toxicity.  
Conclusions: Age ≤ 70 years does not consistently confer a negative 
prognosis in pts with localized prostate cancer. RT appears to be a 
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Purpose/Objective: Theoretically, moderate dose escalation and 
prophylactic pelvic lymph-nodal area (PLNA) irradiation could reduce 
the incidence of treatment failures after salvage radiotherapy for 
biochemical failure (BF) following radical prostatectomy (RP). Aim of 
this study was to investigate the toxicity profile and the early clinical 
outcome of high dose moderately hypofractionated salvage 
Tomotherapy with PLNA irradiation. 
Materials and Methods: From 7/2007 to 12/2010, 65 patients (pts) 
with BF after radical prostatectomy underwent salvage Tomotherapy 
(TOMOSALV) to the prostatic bed (PB) and prophylactic PLNA 
irradiation. Patient characteristics: median age 67 years, iPSA 10.29 
ng/mL, pathologic stage pT2/pT3a/pT3b 51/8/6; pN0/pNx 57/8, 
median number of pelvic LN removed 10, positive surgical margins 36, 
Gleason score 2-6/7/8-10: 17/38/10. Median interval from RP to PSA 
failure 33.73 months (range 7-127); median PSA doubling time (PSADT) 
8.62 months (range 0.53-36.55), median pre-Tomotherapy PSA 
(PSA@RT) 0.36 ng/mL (range 0,17-8.49). In 6 patients local relapse 
was biopsy confirmed.  
All pts were treated with moderately hypofractionated (28 fractions) 
simultaneous integrated boost (SIB) technique. The dose to PLNA was 
51.8 Gy, 1.85 Gy/fraction. The seminal vesicles bed was always 
irradiated to 61.6 Gy (2.2 Gy/fraction), while the dose to the PB was 
71.4 Gy (72.8 in the case of biopsy confirmed relapse). 21 pts also 
received adjuvant androgen deprivation (AAD) for a median of 24 
months (range 3-37). 
Results: Median follow-up was 41 months. To date, all pts except one 
(death from gastric cancer 14 months after RT completion, bNED) are 
alive. Seven pts (median PSA@RT 0.42 ng/mL, median PSADT 5 
months) experienced BF (defined as a single PSA value >0.20 ng/mL 
after a post-radiotherapy nadir or a continuous rise despite 
irradiation) 25 months after Tomotherapy end and underwent salvage 
hormonotherapy. In 2 of these pts a clinical relapse (in both 
lumboaortic LN) was also observed. The 3-year biochemical relapse-
free survival (bRFS) was 91%, with no difference between patients 
receiving or not AAD (91% vs 90%) and with 4/7 relapsed patients who 
had received AAD. Acute toxicity: 5 Grade 2 (G2) GU, 4 G2 bowel and 
7 G2 proctitis. No G3 or G4.  
Late toxicity: G≥2 GU in 19 (29%), 8 G2, 11 G3. Grade ≥2 proctitis 7 
(11%), 3 G2 and 4 G3. Of note, thus far no Grade ≥2 bowel late 
sequelae have been observed. 
Conclusions: This study suggests that timely moderately 
hypofractionated high dose (EQD2 ≥74-76 Gy) TOMOSALV with 
prophylactic PLNA irradiation is feasible and burdened by only mild 
acute and late gastrointestinal side effects, while GU toxicity was not 
insignificant. 
The >90% 3-year bRFS compares more than favourably with the 
literature data, suggesting a possible benefit deriving from both PLNA 
irradiation and moderate dose escalation, though a more refined 
modelling of factors influencing GU toxicity is needed. 
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Purpose/Objective: To assess the impact of Choline-PET in treatment 
planning of prostate cancer (PCa) patients eligible for radiation 
therapy (RT). 
Materials and Methods: We prospectively enrolled 20 consecutive 
patients (mean age 70.4years, range 58-84) referred to our 
department for RT planning with radical intent (n=2) or assavage 
therapy (n=18). Patient were submitted to a single-day protocol, 
including dedicated CT scan of the pelvis and Choline-PET. Gross-
tumor volumes (GTV) , clinical-tumor volumes(CTV), planning-tumor 
volumes (PTV) and organs at risk (OAR) were outlined on CT with 
Eclipse Varian Medical System software, whereas GTV-PET was 
defined as areas with pathologic uptake and contoured with PETVCAR 
software on Adwantage GE workstation. 
Results: According to the imaging findings, in 14/20 patients the 
indication for RT was confirmed: in 2 cases it was limited to the 
prostatic bed, in 7 cases RT was extended to the entire pelvis, and in 
5 patients, treatment was performed on extra-pelvicorgans. In 30% of 
cases (6/20), either a negative scan or evidence of extensive disease 
at PET addressed patients to other treatment options. Overall 
Choline-PET determined a modification in patient management in 75% 
of cases(15/20): in 7 patient the impact was exerted directly in 
treated volumes, whereas a specific boost in PET-positive lesions was 
given to 50% of all irradiated patients (7/14). 
Conclusions: Choline-PET can have a significant impact on RT 
planning of PCa patients. The influence in therapeutic decision is seen 
up to 75% of cases, and in 1/3 of patients unnecessary RT can be 
avoided. 
 
 
 
 
 
 
